Recently, the Class 1 innovative drug Zorifertinib Hydrochloride Tablets (trade name: 泽瑞尼) of Alpha Biopharma (Jiangsu) Co., Ltd. is approved for marketing by China NMPA. This drug is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutation with central nervous system (CNS) metastases, providing a new treatment option for patients.